Integrin αvβ3 acting as membrane receptor for thyroid hormones mediates angiogenesis in malignant T cells

Blood

Volumn 125, Issue 5, 2015, Pages 841-851

  Cayrol, Florencia ^a   Flaqué, María Celeste Díaz ^a   Fernando, Tharu ^b   Yang, Shao Ning ^b   Sterle, Helena Andrea ^a   Bolontrade, Marcela ^c   Amorós, Mariana ^c   Isse, Blanca ^d   Farías, Ricardo Norberto ^d   Ahn, Haelee ^b   Tian, Ye F ^e   Tabbò, Fabrizio ^b   Singh, Ankur ^e   Inghirami, Giorgio ^b   Cerchietti, Leandro ^b   Cremaschi, Graciela Alicia ^a,f  

^a PONTIFICIA UNIVERSIDAD CATÓLICA ARGENTINA   (Argentina)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c FUNDACIÓN INSTITUTO LELOIR   (Argentina)

^d UNIVERSIDAD NACIONAL DE TUCUMÁN   (Argentina)

^e School of Operations Research and Industrial Engineering   (United States)

^f UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CYCLIN B1; CYCLINE; THYROID HORMONE RECEPTOR; VASCULOTROPIN; VITRONECTIN RECEPTOR; CILENGITIDE; SMALL INTERFERING RNA; SNAKE VENOM; THYROID HORMONE; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER REGRESSION; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DNA SYNTHESIS; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T CELL LYMPHOMA; T LYMPHOCYTE; TUMOR VOLUME; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER TRANSPLANTATION; CELL MOTION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; JURKAT CELL LINE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SCID MOUSE; TUMOR CELL CULTURE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTEGRIN ALPHAVBETA3; JURKAT CELLS; LYMPHOMA, T-CELL; MALE; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SNAKE VENOMS; T-LYMPHOCYTES; THYROID HORMONES; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84921855047     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-07-587337     Document Type: Article

References (30)

1. Armitage JO. The aggressive peripheral T-cell lymphomas: 2013. Am J Hematol. 2013;88(10):910-918.
2. Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K. Peripheral T-cell lymphoma. Blood. 2011;117(25):6756-6767.
3. Reddy NM, Evens AM. Chemotherapeutic advancements in peripheral T-cell lymphoma. Semin Hematol. 2014;51(1):17-24.
4. Skarbnik AP, Burki M, Pro B. Peripheral T-cell lymphomas: a review of current approaches and hopes for the future. Front Oncol. 2013;3:138.
5. Rosenquist R, Davi F, Ghia P. The microenvironment in lymphomas - dissecting the complex crosstalk between tumor cells and 'bystander' cells. Semin Cancer Biol. 2014;24:1-2.
6. Gaulard P, de Leval L. The microenvironment in T-cell lymphomas: emerging themes. Semin Cancer Biol. 2014;24:49-60.
7. Vacca A, Ria R, Presta M, et al. alpha(v)beta(3) integrin engagement modulates cell adhesion, proliferation, and protease secretion in human lymphoid tumor cells. Exp Hematol. 2001;29(8):993-1003.
8. Sloan EK, Pouliot N, Stanley KL, et al. Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone. Breast Cancer Res. 2006;8(2):R20.
9. Bergh JJ, Lin HY, Lansing L, et al. Integrin alphaVbeta3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology. 2005;146(7):2864-2871.
10. Davis PJ, Davis FB, Mousa SA, Luidens MK, Lin HY. Membrane receptor for thyroid hormone: physiologic and pharmacologic implications. Annu Rev Pharmacol Toxicol. 2011;51:99-115.
11. Cheng SY, Leonard JL, Davis PJ. Molecular aspects of thyroid hormone actions. Endocr Rev. 2010;31(2):139-170.
12. Davis PJ. Integrated nongenomic and genomic actions of thyroid hormone on blood vessels. Curr Opin Endocrinol Diabetes Obes. 2011;18(5):293-294.
13. Barreiro Arcos ML, Gorelik G, Klecha A, Genaro AM, Cremaschi GA. Thyroid hormones increase inducible nitric oxide synthase gene expression downstream from PKC-zeta in murine tumor T lymphocytes. Am J Physiol Cell Physiol. 2006;291(2):C327-C336.
14. Barreiro Arcos ML, Sterle HA, Paulazo MA, et al. Cooperative nongenomic and genomic actions on thyroid hormone mediated-modulation of T cell proliferation involve up-regulation of thyroid hormone receptor and inducible nitric oxide synthase expression. J Cell Physiol. 2011;226(12):3208-3218.
15. Patel RG, Purwada A, Cerchietti L, et al. Microscale bioadhesive hydrogel arrays for cell engineering applications. Cell Mol Bioeng. 2014;7(3):394-408.
16. Singh A, Qin H, Fernandez I, et al. An injectable synthetic immune-priming center mediates efficient T-cell class switching and T-helper 1 response against B cell lymphoma. J Control Release. 2011;155(2):184-192.
17. Mas-Moruno C, Rechenmacher F, Kessler H. Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med Chem. 2010;10(10):753-768.
18. Konstantinou K, Yamamoto K, Ishibashi F, et al. Angiogenic mediators of the angiopoietin system are highly expressed by CD10-positive lymphoma cells in angioimmunoblastic T-cell lymphoma. Br J Haematol. 2009;144(5):696-704.
19. Zhang W, Wang L, Zhou D, Cui Q, Zhao D, Wu Y. Expression of tumor-associated macrophages and vascular endothelial growth factor correlates with poor prognosis of peripheral T-cell lymphoma, not otherwise specified. Leuk Lymphoma. 2011;52(1):46-52.
20. Jørgensen JM, Sørensen FB, Bendix K, et al. Expression level, tissue distribution pattern, and prognostic impact of vascular endothelial growth factors VEGF and VEGF-C and their receptors Flt-1, KDR, and Flt-4 in different subtypes of non-Hodgkin lymphomas. Leuk Lymphoma. 2009;50(10):1647-1660.
21. Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer. 2013;13(12):871-882.
22. Zhao WL, Mourah S, Mounier N, et al. Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression. Lab Invest. 2004;84(11):1512-1519.
23. Piccaluga PP, Agostinelli C, Califano A, et al. Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation. Cancer Res. 2007;67(22):10703-10710.
24. Martin-Subero JI, Ammerpohl O, Bibikova M, et al. A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms. PLoS ONE. 2009;4(9):e6986.
25. Raziuddin S, Sheikha A, Abu-Eshy S, Al-Janadi M. Regulation of interleukin-4 production and cytokine-induced growth potential in peripheral T-cell non-Hodgkin's lymphomas. Br J Haematol. 1998;100(2):310-316.
26. Cardoso BA, Martins LR, Santos CI, et al. Interleukin-4 stimulates proliferation and growth of T-cell acute lymphoblastic leukemia cells by activating mTOR signaling. Leukemia. 2009;23(1):206-208.
27. Lamant L, de Reyniés A, Duplantier MM, et al. Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. Blood. 2007;109(5):2156-2164.
28. Calderwood DA, Fujioka Y, de Pereda JM, et al. Integrin beta cytoplasmic domain interactions with phosphotyrosine-binding domains: a structural prototype for diversity in integrin signaling. Proc Natl Acad Sci USA. 2003;100(5):2272-2277.
29. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10(1):9-22.
30. Scaringi C, Minniti G, Caporello P, Enrici RM. Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results. Anticancer Res. 2012;32(10):4213-4223.